Related Experiment Video
Updated: Aug 5, 2026
07:54
Drug-Induced Sleep Endoscopy (DISE) with Target Controlled Infusion (TCI) and Bispectral Analysis in Obstructive Sleep Apnea
Published on: December 6, 2016
Current Updates on Pharmacotherapy for Obstructive Sleep Apnea
1Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. basilent@snubh.org.
Summary
New pharmacological treatments show promise for obstructive sleep apnea (OSA) patients who cannot tolerate positive airway pressure (PAP) therapy. Targeted therapies, including weight loss drugs, are improving AHI scores and offering effective alternatives.
Area of Science:
- Sleep Medicine
- Pharmacology
- Cardiovascular Disease
Background:
- Obstructive sleep apnea (OSA) is a prevalent sleep disorder linked to significant cardiovascular risks.
- Positive airway pressure (PAP) is the standard treatment, but poor adherence limits its effectiveness.
- Developing safe and effective pharmacological alternatives for OSA is crucial.
Purpose of the Study:
- To review advances in pharmacological treatments for obstructive sleep apnea.
- To explore the potential of precision pharmacotherapy based on OSA endotypes.
- To evaluate emerging drug therapies, including dual-drug combinations and anti-obesity medications.
Main Methods:
- Review of early single-agent therapies (protriptyline, acetazolamide).
- Analysis of recent dual-drug combinations (atomoxetine plus oxybutynin).
- Evaluation of glucagon-like peptide-1 receptor agonists and tirzepatide for obesity-related OSA.
Main Results:
- Atomoxetine plus oxybutynin demonstrated significant apnea-hypopnea index (AHI) reduction.
- Tirzepatide achieved substantial weight loss (~20%) and AHI reduction (>50%) in OSA patients.
- Emerging therapies show greater promise than earlier single-agent approaches.
Conclusions:
- Precision pharmacotherapy targeting OSA endotypes and metabolic factors is a promising approach.
- Weight loss medications like tirzepatide represent a significant advancement in managing obesity-related OSA.
- Further research on long-term safety and cost-effectiveness is needed for broad clinical integration.
Related Concept Videos
01:21Sleep Apnea
Sleep apnea is a condition where breathing stops intermittently during sleep, often leading to significant health issues. Each episode can last from 10 to 20 seconds or more and is frequently accompanied by a brief arousal from sleep. This disturbance, largely unnoticed by the individual, can lead to severe daytime fatigue. Commonly, individuals seek help after being informed by their partners about loud snoring and noticeable breathing pauses during sleep.
The condition is more prevalent among...
The condition is more prevalent among...
01:19Management of Insomnia
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications